Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in MelanomaJesper Pedersen, Martin R. Jakobsen, Ninna Aggerholm‐Pedersen et al.|Cancers|2022Cited by 22
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panelJudit Kisistók, Nicolai J. Birkbak, Ditte S. Christensen et al.|Melanoma Research|2023Cited by 4